187 related articles for article (PubMed ID: 27626487)
1. Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Tveita A; Fauskanger M; Bogen B; Haabeth OA
Oncotarget; 2016 Oct; 7(41):67175-67182. PubMed ID: 27626487
[TBL] [Abstract][Full Text] [Related]
2. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
4. Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Tveita AA; Schjesvold F; Haabeth OA; Fauskanger M; Bogen B
Cancer Res; 2015 Aug; 75(16):3268-78. PubMed ID: 26038231
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
6. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.
Pietra BA; Wiseman A; Bolwerk A; Rizeq M; Gill RG
J Clin Invest; 2000 Oct; 106(8):1003-10. PubMed ID: 11032860
[TBL] [Abstract][Full Text] [Related]
7. CD4
Bogen B; Fauskanger M; Haabeth OA; Tveita A
Cancer Immunol Immunother; 2019 Nov; 68(11):1865-1873. PubMed ID: 31448380
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
9. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
10. CD4
Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
[TBL] [Abstract][Full Text] [Related]
11. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
12. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
13. Killing of rat adenocarcinoma 13762 in situ by adoptive transfer of CD4+ anti-tumor T cells requires tumor expression of cell surface MHC class II molecules.
Frey AB; Cestari S
Cell Immunol; 1997 May; 178(1):79-90. PubMed ID: 9184701
[TBL] [Abstract][Full Text] [Related]
14. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
15. Primary antitumor immune response mediated by CD4+ T cells.
Corthay A; Skovseth DK; Lundin KU; Røsjø E; Omholt H; Hofgaard PO; Haraldsen G; Bogen B
Immunity; 2005 Mar; 22(3):371-83. PubMed ID: 15780993
[TBL] [Abstract][Full Text] [Related]
16. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
Lauritzsen GF; Bogen B
Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
[TBL] [Abstract][Full Text] [Related]
17. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
18. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
[TBL] [Abstract][Full Text] [Related]
19. Increased numbers and suppressive activity of regulatory CD25(+)CD4(+) T lymphocytes in the absence of CD4 engagement by MHC class II molecules.
Shen X; Niu C; König R
Cell Immunol; 2013 Apr; 282(2):117-28. PubMed ID: 23770721
[TBL] [Abstract][Full Text] [Related]
20. Acute rejection of orthotopic corneal xenografts in mice depends on CD4(+) T cells and self-antigen-presenting cells.
Tanaka K; Sonoda K; Streilein JW
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2878-84. PubMed ID: 11687532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]